title: Photochemical internalization of bleomycin is superior to photodynamic therapy due to the therapeutic effect in the tumor periphery.
abstract: Photochemical internalization (PCI) is under development for clinical use in treatment of soft tissue sarcomas and other solid tumors. PCI may release endocytosed bleomycin (BLM) into the cytosol by photochemical rupture of the endocytic vesicles. In this study, the human fibrosarcoma xenograft HT1080 was transplanted into the leg muscle of athymic mice. The photosensitizer disulfonated aluminum phthalocyanine (AlPcS(2a)) and BLM were systemically administrated 48 h and 30 min, respectively, prior to light exposure at 670 nm (30 J cm(-2)). The purposes of this study were to evaluate the treatment response to AlPcS(2a)-photodynamic therapy (PDT) and AlPcS(2a)-PDT in combination with BLM (i.e. PCI of BLM) in an orthotopic, invasive and clinically relevant tumor model and to explore the underlying response mechanisms caused by PDT and PCI of BLM. The treatment response was evaluated by measuring tumor growth, contrast-enhanced magnetic resonance imaging (CE-MRI), histology and fluorescence microscopy. The results show that PCI of BLM is superior to PDT in inducing tumor growth retardation and acts synergistically as compared to the individual treatment modalities. The CE-MRI analyses 2 h after AlPcS(2a)-PDT and PCI of BLM identified a treatment-induced nonperfused central zone of the tumor and a well-perfused peripheral zone. While there were no differences in the vascular response between PDT and PCI, the histological analyses showed that PDT caused necrosis in the tumor center and viable tumor cells were found in the tumor periphery. PCI caused larger necrotic areas and the regrowth in the peripheral zone was almost completely inhibited after PCI. The results indicate that PDT is less efficient in the tumor periphery than in the tumor center and that the treatment effect of PCI is superior to PDT in the tumor periphery.
authors.affiliation: Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Montebello, Norway. oleno@radiumhospitalet.no
authors.forename: Ole-Jacob
authors.initials: OJ
authors.lastname: Norum
authors.forename: Jon-Vidar
authors.initials: JV
authors.lastname: Gaustad
authors.forename: Even
authors.initials: E
authors.lastname: Angell-Petersen
authors.forename: Einar K
authors.initials: EK
authors.lastname: Rofstad
authors.forename: Qian
authors.initials: Q
authors.lastname: Peng
authors.forename: Karl-Erik
authors.initials: KE
authors.lastname: Giercksky
authors.forename: Kristian
authors.initials: K
authors.lastname: Berg
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D006801:Humans; D008279:Magnetic Resonance Imaging; D051379:Mice; D008819:Mice, Nude; D008856:Microscopy, Fluorescence; D010777:Photochemistry
chemical_list: D000970:Antineoplastic Agents; D001761:Bleomycin